Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography)

1
Why Biosimilars superior to Biologics?
2
105 Pages Report
95 Pages Report
108 Pages Report
86 Pages Report
112 Pages Report
145 Pages Report
114 Pages Report
140 Pages Report
184 Pages Report
Published Date 15 April 2014
Published Date 21 April 2014
Published Date 1 July 2014
Published Date 07 April 2014
Published Date 25 June 2014
Published Date 30 June 2014
Published Date 18 March 2014
Published Date 08 April 2014
3
Introduction
Table of Content

• Introduction
• Executive Summary
• Global 3D Technology Market Overview
• Global 3D Technology Market by Products
• Global 3D Technology Market by Applications
• Global 3D Technology Market by Geography
• Company Profiles

Key Audiences
Scope of the Report
Key Benefits
4
Table of Contents

• INTRODUCTION
• EXECUTIVE SUMMARY
• MARKET OVERVIEW
• GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY
  TECHNOLOGY
• GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY
  PRODUCT TYPE
• GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY
  APPLICATIONS
• GLOBAL BIOSIMILARS / FOLLOW-ON-BIOLOGICS MARKET
  BY SERVICES
• GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY
  GEOGRAPHIES
• KEY PRODUCTS AND RECENT ACTIVITIES BY GEOGRAPHY
• 10 . COMPANY PROFILES

5
Description
Biosimilars or follow-on-biologics are the
copied version of reference biologics, which
are protected by intellectual rights that will
expire soon. Patent expiration is the major
driving factor of the biosimilars market. Most of
the blockbuster patents will expire by the end of
2014, which would provide a competitive edge to
local pharmaceutical manufacturers over the
global players. For instance, patents for
insulin glargine will expire by the end of this
year, which would give an opportunity for the
growth of insulin biosimilars market. Global
biosimilars/follow-on-biologics market accounted
for 1,358 million in 2013 and it is anticipated
to generate 35,032 million by 2020, growing at a
CAGR of 60.8 from 2014 to 2020. Regulations for
biosimilars plays a vital role in maintaining the
viability and balance between original and
biosimilar products. Various regulatory
authorities, namely EMA and the U.S. FDA are
actively regulating the biosimilars market.
Regulations in the European union are considered
benchmark around the world, as the guidelines
proposed are most stringent for validation and
commercialization of biosimilars. High
profitability is the attractive aspect that is
enticing companies to invest in the biosimilars
industry. 
6
KEY BENEFITS

• The study is segmented in a strategic divisions
  to gain deeper insights into the market dynamics
  and understand the competitive environment of the
  overall market 
• Financial market forecast is provided for the
  next eight years by considering 2013 as the base
  year
• Comprehensive and quantitative data about
  changing market trends, intensifying competition
  and opportunities in biosimilars market are
  provided to make better business decisions
• Porters Five Forces model and SWOT analysis of
  the overall market is provided to help
  stakeholders gain strategic insights of the
  market
• Deep dive analysis of key market players and
  strategies adopted by them are expounded to
  provide valuable information on the top
  contenders in the market
• Identification of key investment pockets for the
  biosimilars market is strategically dealt to
  assist the stakeholders 

7
Global Biosimilars Market Overview

  Diverse approach of global regulators towards
biosimilars
Market Definition and Scope

  Safety issues of  biosimilar drugs

  Value chain analysis
Global Biosimilars Market Overview
Porters five force analysis
Key Findings
Emerging economies a hotspot for biosimilars
market
Regulation Reimbursement scenario
8
Market Dynamics
Your feedback is important to us
What would you like to know more about this Study
?

• Global Industry Analysis
• Market Size
• Market Share
• Market Trends
• Opportunities and Forecast

High prevalence of chronic diseases among
population
Growing pressure to reduce healthcare expenditure
Various blockbusters going off patent
Lower cost biosimilars drugs than original
biologics
Medical Efficacy and Patient Safety
High initial investment in research and
development
Please inform us on http//www.alliedmarketresea
rch.com/contact-us
Economic and scientific obstacles
9
GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET By
APPLICATIONS
10
GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS  MARKET BY
TECHNOLOGIES
Monoclonal Antibodies (MAb) Technology
Recombinant DNA Technology
Chromatography
Market By Technologies
Nuclear magnetic resonance (NMR) technology
Electrophoresis
MASS SPECTROMETRY
Western Blotting
Bioassay
11
GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS  MARKET By
, GEOGRAPHY
12
Top Market Players of Biosimilars/Follo-On-Biologi
cs Market

• Novartis (Sandoz)
• Synthon Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• LG Life Sciences
• Celltrion
•   Biocon
• Hospira
• Merck Serono (Merck Group)
• Biogen idec Inc.
• Genentech (Roche Group)

13
Your feedback is important to us
What would you like to know more about this Study
?

• Global Industry Analysis
• Market Size
• Market Share
• Market Trends
• Opportunities and Forecast

Please inform us on http//www.alliedmarketresea
rch.com/contact-us
14
To View the Complete Report
Visit -
http//www.alliedmarketresearch.com/ biosimilars-m
arket